Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Treatment approaches for AL amyloidosis versus ATTR amyloidosis

Efstathios Kastritis, MD, University of Athens, Athens, Greece, discusses different treatment approaches for light chain (AL) amyloidosis versus transthyretin (ATTR) amyloidosis, emphasizing the importance of accurately diagnosing patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.